Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02024386 · ClinicalTrials.gov registry record · Phase 4
Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
A Phase 4 study of Hypertension, Pulmonary and Altitude Sickness, sponsored by Richard Moon.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02024386 is a Phase 4 study of Hypertension, Pulmonary and Altitude Sickness that has completed, run by Richard Moon. The registered enrollment target is 28 participants, below the 742-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02024386, a Phase 4 study of Hypertension, Pulmonary and Altitude Sickness, has completed, sponsored by Richard Moon.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
During ascent to high altitude there is a physiologic response to hypoxia that results in an elevated pulmonary arterial pressure associated with decreased exercise performance, altitude-induced pulmonary hypertension, and high altitude pulmonary edema (HAPE). Riociguat is a novel agent from Bayer Pharmaceuticals that has already demonstrated effectiveness in the treatment of pulmonary hypertension, and it may prove to be beneficial in cases of altitude-induced pulmonary hypertension or HAPE. This research study, composed of 20 healthy volunteers ages 18-40 years, will attempt to mimic the decreased oxygen supply and elevated pulmonary artery pressures found in conditions of high altitude, allowing observation of the effects of riociguat and exercise on pulmonary arterial pressure, arterial oxygenation, and exercise performance. Prior to entering the hypobaric chamber, subjects will have radial arterial lines and pulmonary artery catheters placed to obtain arterial and pulmonary artery pressure measurements. Subjects will then enter the hypobaric chamber and perform exercise tolerance tests at a simulated altitude of 15,000 feet on an electrically braked ergometer (exercise bike) before and after administration of riociguat. If, after administration of riociguat and exposure to a simulated altitude of 15,000 feet, the exercise performance is improved and observed pulmonary artery pressures are lower than those measurements seen prior to administration of riociguat, this could lead to development of a prophylactic and/or treatment strategy for HAPE and high-altitude pulmonary hypertension. Statistical analysis will compare the variables of pulmonary artery pressure, radial arterial pressure, ventilation rate, cardiac output, PaO2, and work rate at exhaustion before and after administration of the drug riociguat. The investigator's hypothesis is that riociguat will decrease pulmonary artery pressure and improve gas exchange and exercise performance at altitude.
Conditions Studied
Interventions
- DRUG Riociguat
Study Locations (1)
North Carolina
- Duke Center for Hyperbaric Medicine and Environmental Physiology, Trent Drive, Building CR2, Room 0584, Box 3823, - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02024386
The ClinicalTrials.gov registry entry for NCT02024386 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 742-participant average among 10 other Hypertension, Pulmonary trials with a reported enrollment target (96% lower). The listed sponsor is Richard Moon, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension, Pulmonary appearing as the primary indexed condition, and to 1 intervention - of which Riociguat is the first listed.
NCT02024386 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02024386 about?
NCT02024386 is a clinical study titled "Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude". During ascent to high altitude there is a physiologic response to hypoxia that results in an elevated pulmonary arterial pressure associated with decreased exercise performance, altitude-induced pulmonary hypertension, and high altitude pulmonary edema (HAPE). Riociguat is a novel agent from Bayer P...
What is the current status of trial NCT02024386?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2014-01. Estimated completion is 2015-12.
What conditions does trial NCT02024386 study?
This clinical trial studies the following conditions: Hypertension, Pulmonary, Altitude Sickness.
What interventions are being tested in trial NCT02024386?
The interventions under investigation include: Riociguat (DRUG).
Who is sponsoring clinical trial NCT02024386?
This trial is sponsored by Richard Moon, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02024386 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension, Pulmonary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
RECRUITING
-
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
RECRUITING · Phase 2
-
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
ACTIVE NOT RECRUITING · Phase 2
-
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
ACTIVE NOT RECRUITING · NA
-
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.